Evidence map›Paper›PMID 41809262›Full record

ArticleAsian journal of pharmaceutical sciences2025

Stealth hemostatic anchors with vWF-driven navigation and plasmin-triggered tranexamic release for hematoma containment in cerebral hemorrhage.

Yu-E Wang, Haoqi Wang, Shanshan Han, Dong Cen, Zibin Zhang, Ke Xiao, Likun Wang, Xingjie Wu, Qianqian Guo, Ling Tao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu-E WangDepartment of Cardiovascular medicine, Affiliated Hospital of Guizhou Medical University, Guiyang 550025, China.
Haoqi WangAffiliated Hospital / School of Clinical Medicine, Guizhou Meidical University, Guiyang 550025, China.
Shanshan HanAffiliated Hospital / School of Clinical Medicine, Guizhou Meidical University, Guiyang 550025, China.
Dong CenThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicianl Pharmacology and Druggability, Guizhou Medical University, Guiyang 561113, China.
Zibin ZhangGuizhou Jinjiu Biotechnology Co., Ltd., Guiyang 550000, China.
Ke XiaoGuizhou Jinjiu Biotechnology Co., Ltd., Guiyang 550000, China.
Likun WangAffiliated Hospital / School of Clinical Medicine, Guizhou Meidical University, Guiyang 550025, China.
Xingjie WuThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicianl Pharmacology and Druggability, Guizhou Medical University, Guiyang 561113, China.
Qianqian GuoThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicianl Pharmacology and Druggability, Guizhou Medical University, Guiyang 561113, China.
Ling TaoThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicianl Pharmacology and Druggability, Guizhou Medical University, Guiyang 561113, China.
Wei LiDepartment of Cardiovascular medicine, Affiliated Hospital of Guizhou Medical University, Guiyang 550025, China.
Xiangchun ShenThe High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the High Educational Key Laboratory of Guizhou Province for Natural Medicianl Pharmacology and Druggability, Guizhou Medical University, Guiyang 561113, China.
Guofeng WuAffiliated Hospital / School of Clinical Medicine, Guizhou Meidical University, Guiyang 550025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high mortality and disability rates associated with spontaneous intracerebral hemorrhage (sICH) are primarily attributed to secondary injuries caused by hematoma expansion from continuous bleeding or rehemorrhage. Rapid hemostasis to prevent hematoma progression is critical in clinical emergencies for improving surgical outcomes and patient prognosis. For internal hemorrhages inaccessible to external interventions, especially for sICH, intravenous hemostatic strategies are essential regardless of ultimate surgical eligibility. This study reported a stealth hemostatic anchor system based on peptide-drug conjugates. Tranexamic acid (TXA), a clinically approved antifibrinolytic agent, served as the hemostatic component, while a von Willebrand factor (vMF)-binding peptide (VBP) enabled targeted delivery by specifically binding to (vMF) exposed at vascular injury sites. A plasmin-cleavable linker was incorporated to control TXA release, ensuring site-specific drug activation. The plasmin-responsive peptide-drug conjugate (RPDC) was synthesized by covalently linking TXA to VBP via the plasmin-cleavable linker.

Indexed as

Hematoma expansionPeptide drug conjugatesPlasmin-responsiveSpontaneous intracerebral hemorrhageTranexamicVon Willebrand factor

Identifiers

PMID41809262
PMCPMC12550148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.